Table 4.
Correlation between significantly upregulated miRNAs in NAFLD patients and the clinical and biochemical parameters and features of the metabolic syndrome
| Spearman’s rank correlation test (p value) | |||||
| Features | miR-122 | miR-192 | miR-375 | miR-19a/b | miR-125b |
| Liver phenotype-related features | |||||
| ALT, U/L | 0.4 (0.0004) | – | – | – | – |
| AST, U/L | 0.5 (8×10−4) | 0.24 (0.04) | – | – | – |
| GGT, U/L | 0.3 (0.01) | 0.24 (0.04) | – | – | 0.3 (0.03) |
| Metabolic syndrome-related features | |||||
| Plasma triglycerides, mg/dL | 0.32 (0.006) | 0.24 (0.05) | – | – | 0.32 (0.03) |
| BMI, kg/m2 | – | – | – | 0.4 (0.0004) | 0.25 (0.02) |
| Fasting plasma glucose, mg/dL | – | – | – | 0.25 (0.02) | – |
| Soluble intercellular adhesion molecule-1 | – | – | 0.5 (0.01) | 0.4 (0.04) | 0.45 (0.03) |
| Plasminogen activator inhibitor-1 | – | – | – | 0.3 (0.05) | 0.3 (0.05) |
ALT and AST, serum alanine and aspartate aminotransferase; BMI, body mass index; GGT, γ-glutamyl-transferase; NAFLD, non-alcoholic fatty liver disease.